In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

Approval establishes sacituzumab govitecan as a first-line option across PD-L1 strata, including monotherapy when checkpoint inhibitors are unsuitable and combination therapy for PD-L1 CPS ≥10 tumors.

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...

They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...

Clinical Affairs plays a central role in ensuring that CGM promotional claims are accurate, evidence-based, and compliant. By ...

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to ...

Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...

An FDA pilot targeting early clinical development seeks to shorten IND-to–first-patient timelines by six to 12 months, potentially shifting capital allocation, IRR models, and milestone-driven ...

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim ...

Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...